Fatigue and HIIT cycling
Summary
We are investigating how acute fatigue, accumulated fatigue, and pain affects neurological, cardiovascular, metabolic, and psychological responses during high-intensity interval cycling (HIIT). You will be required to attend the Human Performance Lab for a total of 8 sessions. In the first session, you will perform a maximal cycling test to determine your aerobic fitness. In the following sessions, you will perform various HIIT protocols on the bike. The last 5 sessions will be completed in a row (i.e., you will come to the lab 5 days in a row), and this will help us see how this type of training might affect fatigue and influence your performance.
During these sessions, aside from cycling, we will measure you breathing rate, heart rate, and blood lactate (via fingerprick). We will measure your pain threshold using a handheld pressure device. We will also stimulate your femoral nerve and motor cortex to examine your neural pathways. All of these measures are non-invasive (aside from the lactate measure, which is very minimally invasive) and will cause no or very minimal discomfort.
Eligibility
Eligible ages: 18 to 40
Accepts healthy participants: Yes
Inclusion criteria:
We are seeking healthy, recreationally active males and females aged 18-40 years.
Exclusion criteria:
You are not eligible for this study if you:
1) Are obese (BMI>30kg/m^2)
2) Are a smoker
3) Have a mood, neurological, cardiovascular, and/or metabolic disorder
4) Had a lower limb injury within the last 6 months that currently affects ability to exercise (i.e., perform maximal leg extension and/or cycle on a bike)
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
Jenny Zhang
Principal investigator:
Saied Jalal Aboodarda
Clinical trial:
No
REB-ID:
REB23-0756